Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy

European Heart Journal

Volumn 29, Issue 13, 2008, Pages 1653-1661

  Saumarez, Richard C ^a   Pytkowski, Mariusz ^b   Sterlinski, Maciej ^b   Bourke, John P ^c   Clague, Jonathan R ^d   Cobbe, Stuart M ^e   Connelly, Derek T ^e   Griffith, Michael J ^f   McKeown, Pascal P ^g   McLeod, Karen ^h   Morgan, John M ⁱ   Sadoul, Nicolas ^j   Chojnowska, Lidia ^b   Huang, Christopher L H ^a   Grace, Andrew A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSTITUTE OF CARDIOLOGY   (Poland)

^c FREEMAN HOSPITAL   (United Kingdom)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g ROYAL VICTORIA HOSPITAL   (United Kingdom)

^h ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

ⁱ SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^j CHU NANCY BRABOIS   (France)

more..

Author keywords

Cardiomyopathy; Defibrillation; Electrophysiology; Heart arrest

Indexed keywords

ADULT; ANAMNESIS; ARTICLE; CONFIDENCE INTERVAL; DEFIBRILLATOR; ELECTROGRAPHY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PACED ELECTROGRAM FRACTIONATION ANALYSIS; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RESUSCITATION; RISK FACTOR; ROC CURVE; SUDDEN DEATH;

ADOLESCENT; ADULT; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE;

EID: 46849090514     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn111     Document Type: Article

References (35)

1. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-785.
2. Nishimura RA, Ommen SR. Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar? JAMA 2007;298:452-454.
3. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Blanc JJ, Budaj A, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e385-e484.
4. Grace AA, Brady PA, Shapiro LM. Risk management in hypertrophic cardiomyopathy. Lancet 2001;357:407-408.
5. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-412.
6. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-1713.
7. Maisel WH. Transvenous implantable cardioverter-defibrillator leads: the weakest link. Circulation 2007;115:2461-2463.
8. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, Saggau W, Weisse U, Seidl K. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation 2007;115:2474-2480.
9. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004;95:754-763.
10. Kawara T, Derksen R, de Groot JR, Coronel R, Tasseron S, Linnenbank AC, Hauer RN, Kirkels H, Janse MJ, de Bakker JM. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation 2001;104:3069-3075.
11. Saumarez RC, Camm AJ, Panagos A, Gill JS, Stewart JT, de Belder MA, Simpson IA, McKenna WJ. Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation 1992;86:467-474.
12. Saumarez RC, Slade AK, Grace AA, Sadoul N, Camm AJ, McKenna WJ. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy. Circulation 1995;91:2762-2768.
13. Saumarez RC, Grace AA. Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases. Cardiovasc Res 2000;47:11-22.
14. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 2001;88:275-279.
15. Schumacher B, Gietzen FH, Neuser H, Schummelfeder J, Schneider M, Kerber S, Schimpf R, Wolpert C, Borggrefe M. Electrophysiological characteristics of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy and moderate to severe symptoms. Circulation 2005;112:2096-2101.
16. Saumarez RC, Pytkowski M, Sterlinski M, Hauer RN, Derksen R, Lowe MD, Szwed H, Huang CL, Ward DE, Camm AJ, Grace AA. Delayed paced ventricular activation in the long QT syndrome is associated with ventricular fibrillation. Heart Rhythm 2006;3:771-778.
17. Turner I, Huang CL-H, Saumarez RC. Numerical simulation of paced electrogram fractionation: relating clinical observations to changes in fibrosis and action potential duration. J Cardiovasc Electrophysiol 2005;16:151-161.
18. Saumarez RC, Chojnowska L, Derksen R, Pytkowski M, Sterlinski M, Huang CL, Sadoul N, Hauer RN, Ruzyllo W, Grace AA. Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation. Circulation 2003;107:2595-2600.
19. Saumarez RC, Heald S, Gill J, Slade AK, de Belder M, Walczak F, Rowland E, Ward DE, Camm AJ. Primary ventricular fibrillation is associated with increased paced right ventricular electrogram fractionation. Circulation 1995;92:2565-2571.
20. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-2218.
21. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:420- 424.
22. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, Shalaby A, Schaechter A, Subacius H, Kadish A. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006;113:776-782.
23. Zou KH, O'Malley J, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007;115:654-657.
24. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
25. Roden DM. Probing the arrhythmogenic substrate. Heart Rhythm 2006;3:779-780.
26. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650-655.
27. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295- 303.
28. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987-2991.
29. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-1320.
30. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-1785.
31. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-879.
32. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:697-704.
33. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992;86:730-740.
34. Connolly SJ. Use and misuse of surrogate outcomes in arrhythmia trials. Circulation 2006;113:764-766.
35. Hlatky MA. Evidence-based use of cardiac procedures and devices. N Engl J Med 2004;350:2126-2128.